SRT Combined With Anlotinib for the Treatment of Brain Metastases From Non-small Cell Lung Cancer

This study is testing a combination of stereotactic radiosurgery (a very precise form of radiation that targets brain tumors) and anlotinib (an oral targeted drug that blocks blood vessel growth in tumors) for people with non-small cell lung cancer that has spread to the brain. Researchers want to see if combining these two treatments helps control brain metastases better than radiation alone. **You may be eligible if...** - You are between 18 and 80 years old - You have non-small cell lung cancer with brain metastases (up to 5 spots in the brain) - Your cancer is resistant to treatment (EGFR wild-type or EGFR mutant) - You have at least one brain lesion visible on imaging - You are generally healthy (ECOG 0 or 1) and can take oral medications **You may NOT be eligible if...** - You have widely spread cancer through the fluid around the spine or extensive pleural involvement - You have had another cancer in the past 5 years (except certain cured cancers) - You have uncontrolled high blood pressure, active bleeding, or a history of serious GI complications - You have HIV, active Hepatitis B or C, or active tuberculosis - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.